Evidence map›Paper›PMID 36361516›Full record

ReviewInternational journal of molecular sciences2022

Analyses of Transcriptomics Cell Signalling for Pre-Screening Applications in the Integrated Approach for Testing and Assessment of Non-Genotoxic Carcinogens.

Yusuke Oku, Federica Madia, Pierre Lau, Martin Paparella, Timothy McGovern, Mirjam Luijten, Miriam N Jacobs

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 6 countries.

Yusuke OkuThe Organisation for Economic Cooperation and Development (OECD), 2 Rue Andre Pascal, 75016 Paris, France.ORCID 0000-0001-5652-635X
Federica MadiaEuropean Commission, Joint Research Centre (JRC), Via Enrico Fermi, 2749, 21027 Ispra, Italy.ORCID 0000-0002-8438-0957
Pierre LauIstituto Italiano di Tecnologia, 16163 Genova, Italy.
Martin PaparellaInstitute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innbruck, Austria.ORCID 0000-0002-8700-4834
Timothy McGovernUS Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20901, USA.
Mirjam LuijtenCentre for Health Protection, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3721 MA Utrecht, The Netherlands.ORCID 0000-0002-5277-1443
Miriam N JacobsCentre for Radiation, Chemical and Environmental Hazard (CRCE), Public Health England (PHE), Chilton OX11 0RQ, Oxfordshire, UK.
Innsbruck Medical University · ATItalian Institute of Technology · ITJoint Research Centre · ITNational Institute for Public Health and the Environment · NLOrganisation de Coopération et de Développement Economiques · FRPublic Health England · GBUnited States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With recent rapid advancement of methodological tools, mechanistic understanding of biological processes leading to carcinogenesis is expanding. New approach methodologies such as transcriptomics can inform on non-genotoxic mechanisms of chemical carcinogens and can be developed for regulatory applications. The Organisation for the Economic Cooperation and Development (OECD) expert group developing an Integrated Approach to the Testing and Assessment (IATA) of Non-Genotoxic Carcinogens (NGTxC) is reviewing the possible assays to be integrated therein. In this context, we review the application of transcriptomics approaches suitable for pre-screening gene expression changes associated with phenotypic alterations that underlie the carcinogenic processes for subsequent prioritisation of downstream test methods appropriate to specific key events of non-genotoxic carcinogenesis. Using case studies, we evaluate the potential of gene expression analyses especially in relation to breast cancer, to identify the most relevant approaches that could be utilised as (pre-) screening tools, for example Gene Set Enrichment Analysis (GSEA). We also consider how to address the challenges to integrate gene panels and transcriptomic assays into the IATA, highlighting the pivotal omics markers identified for assay measurement in the IATA key events of inflammation, immune response, mitogenic signalling and cell injury.

Indexed as

CarcinogensTranscriptomeBiological AssayCarcinogenesisCarcinogenicity TestsHumansCarcinogenscarcinogenicitygene expressionintegrated approaches to testing and assessment (IATA)non-genotoxic carcinogen(s) (NGTxC(s))organisation for economic co-operation and development (OECD)transcriptomics

Identifiers

PMID36361516
PMCPMC9659232
OpenAlexW4307270556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.